+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Is Reverse Triiodothyronine a Physiological Nonactive Competitor for the Action of Triiodothyronine upon the Electrical Properties of GH 3 Cells?


      S. Karger AG

      GH3 , Triiodothyronine, Reverse triiodothyronine, Conductance, Action potentials, Membrane, Binding site

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The electrical properties of GH<sub>3</sub> cells, a transformed line from the rat pituitary, were studied with a current-clamp technique in the presence of triiodothyronine (T<sub>3</sub>) and reverse triiodothyronine (rT<sub>3</sub>) and compared with the known effects of T<sub>3</sub>. rT<sub>3</sub> had an effect only in a concentration of 1 µ M; action potentials were suppressed, and changes in the slope conductance were similar to those seen in response to T<sub>3</sub>. Membrane resistance R<sub>I</sub> decreased, and the resting membrane potential V<sub>M</sub> hyperpolarized. The action of rT<sub>3</sub> is a 1,000 times less potent than that of T<sub>3</sub> and is unlikely to have a physiological significance. When a cell was beforehand superfused with rT<sub>3</sub> (10 n M), the effect of T<sub>3</sub> was prevented even in a concentration of 10 n M. The specificity of T<sub>3</sub>, the prevention of the effect of T<sub>3</sub> by rT<sub>3</sub>, and the small dose needed suggest a binding site for T<sub>3</sub>. The short latency of its action implies an extranuclear binding site, probably in or near the plasma membrane of the GH<sub>3</sub> cell.

          Related collections

          Author and article information

          S. Karger AG
          07 April 2008
          : 54
          : 2
          : 146-150
          Department of Experimental Zoology, Biologisch Centrum Gebouw II, University of Amsterdam, The Netherlands
          125873 Neuroendocrinology 1991;54:146–150
          © 1991 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 5
          Original Paper


          Comment on this article